CEO, Avidea Technologies
Geoffrey Lynn, Ph.D., is co-founder and CEO of Avidea Technologies, a Hopkins-based start-up that is developing immunotherapies for cancer treatment and infectious disease prevention based on an immunotherapeutic delivery (“Nanoscaffold”) platform. Over the last 12 months, Avidea has raised over $1.5M in financing, primarily through R&D partnerships with Pharmaceutical and Biotechnology companies. These partnerships are helping to propel Avidea’s development of different assets based on the Nanoscaffold platform, including Avidea’s lead asset—a personalized cancer vaccine (PCV). Avidea has demonstrated that the PCV is safe and effective in non-human primates and has successfully completed a pilot GMP manufacturing run. Based on this compelling data, Avidea is now raising Series A financing to advance the PCV to first-in-human testing. Prior to joining Avidea, Geoffrey was a post-doctoral fellow with Robert Seder at the Vaccine Research Center, NIH. Geoffrey has a B.S. in chemistry from Elon University, attended medical school at Johns Hopkins, and has a Ph.D. (“D.Phil.”) in Biomedical Engineering from Oxford University through the NIH-Oxford-Cambridge program.